Hereditary Angioedema Therapeutics Market (2026 - 2033) Size, Share & Trends Analysis Report By Treatment (C1-Inhibitor Concentrates, Bradykinin B2 Receptor Antagonist), By End Use, By Region, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Segment Definitions
                        1.2.1. Treatment
                        1.2.2. End Use
                        1.2.3. Route of Administration
                    1.3. Estimates and Forecast Timeline
                    1.4. Research Methodology
                    1.5. Information Procurement
                        1.5.1. Purchased Database
                        1.5.2. GVR’s Internal Database
                        1.5.3. Secondary Sources
                        1.5.4. Primary Research
                    1.6. Information Analysis
                        1.6.1. Data Analysis Models
                    1.7. Market Formulation & Data Visualization
                    1.8. Model Details
                        1.8.1. Commodity Flow Analysis
                    1.9. List of Secondary Sources
                    1.10. Objectives
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Hereditary Angioedema Therapeutics Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                        3.2.2. Market Restraint Analysis
                    3.3. Business Environment Analysis
                        3.3.1. Industry Analysis - Porter’s Five Forces Analysis
                            3.3.1.1. Supplier Power
                            3.3.1.2. Buyer Power
                            3.3.1.3. Substitution Threat
                            3.3.1.4. Threat of New Entrants
                            3.3.1.5. Competitive Rivalry
                        3.3.2. PESTLE Analysis
                        3.3.3. Pipeline Analysis
                        3.3.4. Patent Expiry Analysis
                        3.3.5. Pricing Analysis
Chapter 4. Hereditary Angioedema Therapeutics Market: Treatment Business Analysis
                    4.1. Treatment Market Share, 2025 & 2033
                    4.2. Treatment Segment Dashboard
                    4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
                    4.4. C1-Inhibitor Concentrates
                        4.4.1. C1-Inhibitor Concentrates Market, 2021 - 2033 (USD Million)
                    4.5. Bradykinin B2 Receptor Antagonist
                        4.5.1. Bradykinin B2 Receptor Antagonist Market, 2021 - 2033 (USD Million)
                    4.6. Kallikrein Inhibitor
                        4.6.1. Kallikrein Inhibitor Market, 2021 - 2033 (USD Million)
                    4.7. Others
                        4.7.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Hereditary Angioedema Therapeutics Market: End Use Business Analysis
                    5.1. End Use Market Share, 2025 & 2033
                    5.2. End Use Segment Dashboard
                    5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
                    5.4. Prophylaxis
                        5.4.1. Prophylaxis Market, 2021 - 2033 (USD Million)
                    5.5. On-demand
                        5.5.1. On-demand Market, 2021 - 2033 (USD Million)
Chapter 6. Hereditary Angioedema Therapeutics Market: Route of Administration Business Analysis
                    6.1. Route of Administration Market Share, 2025 & 2033
                    6.2. Route of Administration Segment Dashboard
                    6.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
                    6.4. Intravenous
                        6.4.1. Intravenous Market, 2021 - 2033 (USD Million)
                    6.5. Subcutaneous
                        6.5.1. Subcutaneous Market, 2021 - 2033 (USD Million)
                    6.6. Oral
                        6.6.1. Oral Market, 2021 - 2033 (USD Million)
Chapter 7. Hereditary Angioedema Therapeutics Market: Regional Estimates & Trend Analysis
                    7.1. Regional Market Share Analysis, 2025 & 2033
                    7.2. Regional Market Dashboard
                    7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
                    7.4. North America
                        7.4.1. North America Hereditary Angioedema Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
                        7.4.2. U.S.
                            7.4.2.1. Key Country Dynamics
                            7.4.2.2. End Use Disease Prevalence
                            7.4.2.3. Regulatory Framework
                            7.4.2.4. Reimbursement Framework
                            7.4.2.5. U.S. Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.3. Canada
                            7.4.3.1. Key Country Dynamics
                            7.4.3.2. End Use Disease Prevalence
                            7.4.3.3. Regulatory Framework
                            7.4.3.4. Reimbursement Framework
                            7.4.3.5. U.S. Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.4.4. Mexico
                            7.4.4.1. Key Country Dynamics
                            7.4.4.2. End Use Disease Prevalence
                            7.4.4.3. Regulatory Framework
                            7.4.4.4. Reimbursement Framework
                            7.4.4.5. Mexico Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Europe
                        7.5.1. Europe Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.2. UK
                            7.5.2.1. Key Country Dynamics
                            7.5.2.2. End Use Disease Prevalence
                            7.5.2.3. Regulatory Framework
                            7.5.2.4. Reimbursement Framework
                            7.5.2.5. Uk Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.3. Germany
                            7.5.3.1. Key Country Dynamics
                            7.5.3.2. End Use Disease Prevalence
                            7.5.3.3. Regulatory Framework
                            7.5.3.4. Reimbursement Framework
                            7.5.3.5. Germany Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.4. France
                            7.5.4.1. Key Country Dynamics
                            7.5.4.2. End Use Disease Prevalence
                            7.5.4.3. Regulatory Framework
                            7.5.4.4. Reimbursement Framework
                            7.5.4.5. France Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.5. Italy
                            7.5.5.1. Key Country Dynamics
                            7.5.5.2. End Use Disease Prevalence
                            7.5.5.3. Regulatory Framework
                            7.5.5.4. Reimbursement Framework
                            7.5.5.5. Italy Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.6. Spain
                            7.5.6.1. Key Country Dynamics
                            7.5.6.2. End Use Disease Prevalence
                            7.5.6.3. Regulatory Framework
                            7.5.6.4. Reimbursement Framework
                            7.5.6.5. Spain Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.7. Denmark
                            7.5.7.1. Key Country Dynamics
                            7.5.7.2. End Use Disease Prevalence
                            7.5.7.3. Regulatory Framework
                            7.5.7.4. Reimbursement Framework
                            7.5.7.5. Denmark Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.8. Sweden
                            7.5.8.1. Key Country Dynamics
                            7.5.8.2. End Use Disease Prevalence
                            7.5.8.3. Regulatory Framework
                            7.5.8.4. Reimbursement Framework
                            7.5.8.5. Sweden Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.5.9. Norway
                            7.5.9.1. Key Country Dynamics
                            7.5.9.2. End Use Disease Prevalence
                            7.5.9.3. Regulatory Framework
                            7.5.9.4. Reimbursement Framework
                            7.5.9.5. Norway Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.6. Asia Pacific
                        7.6.1. Asia Pacific Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.2. Japan
                            7.6.2.1. Key Country Dynamics
                            7.6.2.2. End Use Disease Prevalence
                            7.6.2.3. Regulatory Framework
                            7.6.2.4. Reimbursement Framework
                            7.6.2.5. Japan Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.3. China
                            7.6.3.1. Key Country Dynamics
                            7.6.3.2. End Use Disease Prevalence
                            7.6.3.3. Regulatory Framework
                            7.6.3.4. Reimbursement Framework
                            7.6.3.5. China Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.4. India
                            7.6.4.1. Key Country Dynamics
                            7.6.4.2. End Use Disease Prevalence
                            7.6.4.3. Regulatory Framework
                            7.6.4.4. Reimbursement Framework
                            7.6.4.5. India Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.5. Australia
                            7.6.5.1. Key Country Dynamics
                            7.6.5.2. End Use Disease Prevalence
                            7.6.5.3. Regulatory Framework
                            7.6.5.4. Reimbursement Framework
                            7.6.5.5. Australia Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.6. South Korea
                            7.6.6.1. Key Country Dynamics
                            7.6.6.2. End Use Disease Prevalence
                            7.6.6.3. Regulatory Framework
                            7.6.6.4. Reimbursement Framework
                            7.6.6.5. South Korea Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.6.7. Thailand
                            7.6.7.1. Key Country Dynamics
                            7.6.7.2. End Use Disease Prevalence
                            7.6.7.3. Regulatory Framework
                            7.6.7.4. Reimbursement Framework
                            7.6.7.5. Thailand Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.7. Latin America
                        7.7.1. Latin America Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.7.2. Brazil
                            7.7.2.1. Key Country Dynamics
                            7.7.2.2. End Use Disease Prevalence
                            7.7.2.3. Regulatory Framework
                            7.7.2.4. Reimbursement Framework
                            7.7.2.5. Japan Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.7.3. Argentina
                            7.7.3.1. Key Country Dynamics
                            7.7.3.2. End Use Disease Prevalence
                            7.7.3.3. Regulatory Framework
                            7.7.3.4. Reimbursement Framework
                            7.7.3.5. China Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.8. Middle East and Africa
                        7.8.1. Middle East and Africa Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.8.2. South Africa
                            7.8.2.1. Key Country Dynamics
                            7.8.2.2. End Use Disease Prevalence
                            7.8.2.3. Regulatory Framework
                            7.8.2.4. Reimbursement Framework
                            7.8.2.5. South Africa Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.8.3. Saudi Arabia
                            7.8.3.1. Key Country Dynamics
                            7.8.3.2. End Use Disease Prevalence
                            7.8.3.3. Regulatory Framework
                            7.8.3.4. Reimbursement Framework
                            7.8.3.5. Saudi Arabia Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.8.4. UAE
                            7.8.4.1. Key Country Dynamics
                            7.8.4.2. End Use Disease Prevalence
                            7.8.4.3. Regulatory Framework
                            7.8.4.4. Reimbursement Framework
                            7.8.4.5. UAE Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                        7.8.5. Kuwait
                            7.8.5.1. Key Country Dynamics
                            7.8.5.2. End Use Disease Prevalence
                            7.8.5.3. Regulatory Framework
                            7.8.5.4. Reimbursement Framework
                            7.8.5.5. Kuwait Hereditary Angioedema Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Participant Overview
                    8.2. Company Market Position Analysis
                    8.3. Company Categorization
                    8.4. Strategy Mapping
                    8.5. Company Profiles/Listing
                        8.5.1. BioCryst Pharmaceuticals, Inc.
                            8.5.1.1. Overview
                            8.5.1.2. Financial Performance
                            8.5.1.3. Treatment Benchmarking
                            8.5.1.4. Strategic Initiatives
                        8.5.2. Ionis Pharmaceuticals
                            8.5.2.1. Overview
                            8.5.2.2. Financial Performance
                            8.5.2.3. Treatment Benchmarking
                            8.5.2.4. Strategic Initiatives
                        8.5.3. CSL
                            8.5.3.1. Overview
                            8.5.3.2. Financial Performance
                            8.5.3.3. Treatment Benchmarking
                            8.5.3.4. Strategic Initiatives
                        8.5.4. Attune Pharmaceuticals
                            8.5.4.1. Overview
                            8.5.4.2. Financial Performance
                            8.5.4.3. Treatment Benchmarking
                            8.5.4.4. Strategic Initiatives
                        8.5.5. Adverum Biotechnologies, Inc.
                            8.5.5.1. Overview
                            8.5.5.2. Financial Performance
                            8.5.5.3. Treatment Benchmarking
                            8.5.5.4. Strategic Initiatives
                        8.5.6. KalVista Pharmaceuticals, Inc.
                            8.5.6.1. Overview
                            8.5.6.2. Financial Performance
                            8.5.6.3. Treatment Benchmarking
                            8.5.6.4. Strategic Initiatives
                        8.5.7. Takeda Pharmaceutical Company Limited
                            8.5.7.1. Overview
                            8.5.7.2. Financial Performance
                            8.5.7.3. Treatment Benchmarking
                            8.5.7.4. Strategic Initiatives
                        8.5.8. Pharming
                            8.5.8.1. Overview
                            8.5.8.2. Financial Performance
                            8.5.8.3. Treatment Benchmarking
                            8.5.8.4. Strategic Initiatives
                        8.5.9. Sanofi
                            8.5.9.1. Overview
                            8.5.9.2. Financial Performance
                            8.5.9.3. Treatment Benchmarking
                            8.5.9.4. Strategic Initiatives
                        8.5.10. Pharvaris B.V.
                            8.5.10.1. Overview
                            8.5.10.2. Financial Performance
                            8.5.10.3. Treatment Benchmarking
                            8.5.10.4. Strategic Initiatives
                        8.5.11. Arrowhead Pharmaceuticals, Inc.
                            8.5.11.1. Overview
                            8.5.11.2. Financial Performance
                            8.5.11.3. Treatment Benchmarking
                            8.5.11.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global hereditary angioedema therapeutics market, by region, 2021 - 2033 (USD Million)
Table 4 Global hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 5 Global hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 6 Global hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 7 North America hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
Table 8 North America hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 9 North America hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 10 North America hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 11 U.S. hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 12 U.S. hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 13 U.S. hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 14 Canada hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 15 Canada hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 16 Canada hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 17 Mexico hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 18 Mexico hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 19 Mexico hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 20 Europe hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
Table 21 Europe hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 22 Europe hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 23 Europe hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 24 UK hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 25 UK hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 26 UK hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 27 Germany hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 28 Germany hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 29 Germany hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 30 France hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 31 France hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 32 France hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 33 Italy hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 34 Italy hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 35 Italy hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 36 Spain hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 37 Spain hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 38 Spain hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 39 Norway hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 40 Norway hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 41 Norway hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 42 Denmark hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 43 Denmark hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 44 Denmark hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 45 Sweden hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 46 Sweden hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 47 Sweden hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 48 Asia Pacific hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
Table 49 Asia Pacific hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD
Table 50 Asia Pacific hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 51 Asia Pacific hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 52 Japan hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 53 Japan hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 54 Japan hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 55 China hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 56 China hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 57 China hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 58 India hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 59 India hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 60 India hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 61 Australia hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 62 Australia hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 63 Australia hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 64 South Korea hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 65 South Korea hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 66 South Korea hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 67 Thailand hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 68 Thailand hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 69 Thailand hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 70 Latin America hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
Table 71 Latin America hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 72 Latin America hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 73 Latin America hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 74 Brazil hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 75 Brazil hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 76 Brazil hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 77 Argentina hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 78 Argentina hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 79 Argentina hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 80 Middle East & Africa hereditary angioedema therapeutics market, by country, 2021 - 2033 (USD Million)
Table 81 Middle East & Africa hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 82 Middle East & Africa hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 83 Middle East & Africa hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 84 South Africa hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 85 South Africa hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 86 South Africa hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 87 Saudi Arabia hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 88 Saudi Arabia hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 89 Saudi Arabia hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 90 UAE hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 91 UAE hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 92 UAE hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)
Table 93 Kuwait hereditary angioedema therapeutics market, by treatment, 2021 - 2033 (USD Million)
Table 94 Kuwait hereditary angioedema therapeutics market, by end use, 2021 - 2033 (USD Million)
Table 95 Kuwait hereditary angioedema therapeutics market, by route of administration, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Hereditary angioedema therapeutics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 Hereditary angioedema therapeutics market dynamics
Fig. 11 Hereditary angioedema therapeutics market: Porter’s five forces analysis
Fig. 12 Hereditary angioedema therapeutics market: PESTLE analysis
Fig. 13 Treatment market, 2021 - 2033 (USD Million)
Fig. 14 C1-Inhibitor Concentrates market, 2021 - 2033 (USD Million)
Fig. 15 Bradykinin B2 Receptor Antagonist market, 2021 - 2033 (USD Million)
Fig. 16 Kallikrein Inhibitor market, 2021 - 2033 (USD Million)
Fig. 17 Others market, 2021 - 2033 (USD Million)
Fig. 18 End Use market, 2021 - 2033 (USD Million)
Fig. 19 Prophylaxis market, 2021 - 2033 (USD Million)
Fig. 20 On-demand market, 2021 - 2033 (USD Million)
Fig. 21 Route of administration market, 2021 - 2033 (USD Million)
Fig. 22 Intravenous market, 2021 - 2033 (USD Million)
Fig. 23 Subcutaneous market, 2021 - 2033 (USD Million)
Fig. 24 Oral market, 2021 - 2033 (USD Million)
Fig. 25 Hereditary angioedema therapeutics market revenue, by region
Fig. 26 Regional marketplace: Key takeaways
Fig. 27 North America Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 28 U.S. country dynamics
Fig. 29 U.S. Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 30 Canada country dynamics
Fig. 31 Canada Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 32 Mexico country dynamics
Fig. 33 Mexico Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 34 Europe Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 35 UK country dynamics
Fig. 36 UK Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 37 Germany country dynamics
Fig. 38 Germany Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 39 France country dynamics
Fig. 40 France Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 41 Italy country dynamics
Fig. 42 Italy Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 43 Spain country dynamics
Fig. 44 Spain Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 45 Norway country dynamics
Fig. 46 Norway Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 47 Sweden country dynamics
Fig. 48 Sweden Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 49 Denmark country dynamics
Fig. 50 Denmark Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 51 Asia Pacific Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 52 Japan country dynamics
Fig. 53 Japan Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 54 China country dynamics
Fig. 55 China Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 56 India country dynamics
Fig. 57 India Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 58 Australia country dynamics
Fig. 59 Australia Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 60 South Korea country dynamics
Fig. 61 South Korea Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 62 Thailand country dynamics
Fig. 63 Thailand Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 64 Latin America Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 65 Brazil country dynamics
Fig. 66 Brazil Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 67 Argentina country dynamics
Fig. 68 Argentina Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 69 MEA Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 70 South Africa country dynamics
Fig. 71 South Africa Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 72 Saudi Arabia country dynamics
Fig. 73 Saudi Arabia Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 74 UAE country dynamics
Fig. 75 UAE Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 76 Kuwait country dynamics
Fig. 77 Kuwait Hereditary angioedema therapeutics market, 2021 - 2033 (USD Million)
Fig. 78 Company categorization
Fig. 79 Company market position analysis
Fig. 80 Strategic framework